Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American males today. Novel and effective treatment such as gene therapy is greatly desired. The early viral based gene therapy uses tissue-nonspecific promoters, which causes unintended toxicity to other normal tissues. In this chapter, we will review the transcriptionally regulated gene therapy strategy for prostate cancer treatment. We will describe the development of transcriptionally regulated prostate cancer gene therapy in the following areas: (1) Comparison of different routes for best viral delivery to the prostate; (2) Study of transcriptionally regulated, prostate-targeted viral vectors: specificity and activity of the transgene under several different prostate-specific promoters were compared in vitro and in vivo; (3) Selection of therapeutic transgenes and strategies for prostate cancer gene therapy (4) Oncolytic virotherapy for prostate cancer. In addition, the current challenges and future directions in this field are also discussed.

Original languageEnglish (US)
Pages (from-to)572-588
Number of pages17
JournalAdvanced Drug Delivery Reviews
Volume61
Issue number7-8
DOIs
StatePublished - Jul 2 2009

Fingerprint

Genetic Therapy
Prostate
Prostatic Neoplasms
Neoplasm Genes
Transgenes
Oncolytic Virotherapy
Second Primary Neoplasms
Viral Genes
Cause of Death
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. / Lu, Yi.

In: Advanced Drug Delivery Reviews, Vol. 61, No. 7-8, 02.07.2009, p. 572-588.

Research output: Contribution to journalReview article

@article{bded74c8dbb44571a8f1163963dd9b75,
title = "Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer",
abstract = "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American males today. Novel and effective treatment such as gene therapy is greatly desired. The early viral based gene therapy uses tissue-nonspecific promoters, which causes unintended toxicity to other normal tissues. In this chapter, we will review the transcriptionally regulated gene therapy strategy for prostate cancer treatment. We will describe the development of transcriptionally regulated prostate cancer gene therapy in the following areas: (1) Comparison of different routes for best viral delivery to the prostate; (2) Study of transcriptionally regulated, prostate-targeted viral vectors: specificity and activity of the transgene under several different prostate-specific promoters were compared in vitro and in vivo; (3) Selection of therapeutic transgenes and strategies for prostate cancer gene therapy (4) Oncolytic virotherapy for prostate cancer. In addition, the current challenges and future directions in this field are also discussed.",
author = "Yi Lu",
year = "2009",
month = "7",
day = "2",
doi = "10.1016/j.addr.2009.03.014",
language = "English (US)",
volume = "61",
pages = "572--588",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "7-8",

}

TY - JOUR

T1 - Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer

AU - Lu, Yi

PY - 2009/7/2

Y1 - 2009/7/2

N2 - Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American males today. Novel and effective treatment such as gene therapy is greatly desired. The early viral based gene therapy uses tissue-nonspecific promoters, which causes unintended toxicity to other normal tissues. In this chapter, we will review the transcriptionally regulated gene therapy strategy for prostate cancer treatment. We will describe the development of transcriptionally regulated prostate cancer gene therapy in the following areas: (1) Comparison of different routes for best viral delivery to the prostate; (2) Study of transcriptionally regulated, prostate-targeted viral vectors: specificity and activity of the transgene under several different prostate-specific promoters were compared in vitro and in vivo; (3) Selection of therapeutic transgenes and strategies for prostate cancer gene therapy (4) Oncolytic virotherapy for prostate cancer. In addition, the current challenges and future directions in this field are also discussed.

AB - Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American males today. Novel and effective treatment such as gene therapy is greatly desired. The early viral based gene therapy uses tissue-nonspecific promoters, which causes unintended toxicity to other normal tissues. In this chapter, we will review the transcriptionally regulated gene therapy strategy for prostate cancer treatment. We will describe the development of transcriptionally regulated prostate cancer gene therapy in the following areas: (1) Comparison of different routes for best viral delivery to the prostate; (2) Study of transcriptionally regulated, prostate-targeted viral vectors: specificity and activity of the transgene under several different prostate-specific promoters were compared in vitro and in vivo; (3) Selection of therapeutic transgenes and strategies for prostate cancer gene therapy (4) Oncolytic virotherapy for prostate cancer. In addition, the current challenges and future directions in this field are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=65749102436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749102436&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2009.03.014

DO - 10.1016/j.addr.2009.03.014

M3 - Review article

VL - 61

SP - 572

EP - 588

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 7-8

ER -